OncogenPub Date : 2019-05-02DOI: 10.35702/ONC.10011
E. Nassif, A. Arsène-Henry, Y. Kirova
{"title":"Cognitive Impairment Secondary to Treatment of Cured Brain Metastases of Triple-Negative Breast Carcinoma","authors":"E. Nassif, A. Arsène-Henry, Y. Kirova","doi":"10.35702/ONC.10011","DOIUrl":"https://doi.org/10.35702/ONC.10011","url":null,"abstract":"Materials and methods: We report the case of a 58 years old women cured of brain metastases from TNBC. Initial diagnosis was of locally advanced inflammatory TNBC for which the patient underwent high-dose neo-adjuvant chemotherapy followed by surgery, radiotherapy and adjuvant chemotherapy. Symptomatic brain metastases were diagnosed 10 months after the end of adjuvant chemotherapy. Whole-brain radiotherapy and stereotactic radiosurgery were rapidly delivered followed by twelve months of chemotherapy.","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48015156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-03-14DOI: 10.35702/ONC.10010
A. Pfadt, D. J. Wheeler
{"title":"Single Subject Studies In Prostate Cancer: How Graphing PSA Test Results And Testosterone Levels Using Process Behavior And Celeration Charts Can Provide Insight And Guide Clinical Decisions","authors":"A. Pfadt, D. J. Wheeler","doi":"10.35702/ONC.10010","DOIUrl":"https://doi.org/10.35702/ONC.10010","url":null,"abstract":"Received : February 21, 2019 Published : March 14, 2019 ABSTRACT Process Behavior Charts and Celeration Charts provide effective ways to visualize the clinical status of a patient with prostate cancer and to evaluate the effectiveness of treatments. Process Behavior Charts allow a definitive answer to the question of whether a change has occurred in spite of the variability of the PSA values, and when changes are occurring the Celeration Chart provides an easy estimate of the rate of growth. Both of these graphic techniques help in the overall understanding of the status of a patient at risk for prostate cancer by placing current PSA values in the context of the history of that patient.","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42910147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-03-14DOI: 10.35702/ONC.10008
K. Rojas, G. Prado-Vázquez, C. Bárcena, L. Trilla-Fuertes, A. Gámez-Pozo, A. Zapater-Moros, M. Ferrer-Gómez, L. Lema, R. García-Martin, A. Maroto, J. L. Rodríguez, C. Mendiola, Juan Ángel Fresno Vara, L. Paz-Ares
{"title":"Tumor-infiltrating Lymphocytes Expression in Stage IIIc/IV of High-grade Serous Ovarian Cancer: Variation with Neoadjuvant Chemotherapy and Prognostic Value","authors":"K. Rojas, G. Prado-Vázquez, C. Bárcena, L. Trilla-Fuertes, A. Gámez-Pozo, A. Zapater-Moros, M. Ferrer-Gómez, L. Lema, R. García-Martin, A. Maroto, J. L. Rodríguez, C. Mendiola, Juan Ángel Fresno Vara, L. Paz-Ares","doi":"10.35702/ONC.10008","DOIUrl":"https://doi.org/10.35702/ONC.10008","url":null,"abstract":"1 Citation: Rojas K (2019). Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade serous ovarian cancer: Variation with neoadjuvant chemotherapy and prognostic value. Oncogen Journal 2(2): 8. Tumor-infiltrating Lymphocytes Expression in Stage IIIc/IV of High-grade Serous Ovarian Cancer: Variation with Neoadjuvant Chemotherapy and Prognostic Value K Rojas1, G Prado-Vazquez2, C Barcena3, L Trilla-Fuertes2, A Gamez-Pozo 2,4, A Zapater-Moros4, M Ferrer-Gomez4, L Lema1, R Garcia-Martin3, A Maroto3, JL Rodriguez3, C Mendiola1, JA Fresno Vara4, L Paz-Ares1 1Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain. 2Biomedica Molecular Medicine SL, Madrid, Spain. 3Department of Pathology, Hospital 12 de Octubre, Madrid, Spain. 4Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz, Madrid, Spain.","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43754338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-03-14DOI: 10.35702/ONC.10009
L. P, Brivio F, Messina G, Vigore L, Rovelli F, Di Fede G
{"title":"A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose II-2 or with Immune Checkpoint Inhibitors","authors":"L. P, Brivio F, Messina G, Vigore L, Rovelli F, Di Fede G","doi":"10.35702/ONC.10009","DOIUrl":"https://doi.org/10.35702/ONC.10009","url":null,"abstract":"1 Citation: Lissoni P (2019). A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose Il-2 or with Immune Checkpoint Inhibitors. Oncogen Journal 2(2): 9. A Clinical Study of Biomarkers to Predict the Efficacy of Cancer Immunotherapy with Subcutaneous Low-Dose Il-2 or with Immune Checkpoint Inhibitors Lissoni P, Brivio F, Messina G, Vigore L, Rovelli F, Di Fede G","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47129216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-03-12DOI: 10.35702/ONC.10007
A. Heidari, J. Esposito, Angela Caissutti
{"title":"The Importance of Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) and Raman Biospectroscopy of Single-Walled Carbon Nanotubes (SWCNT) and Multi- Walled Carbon Nanotubes (MWCNT) in Interpreting Infrared and Raman Spectra of Human Cancer Cells, Tissues and Tumors","authors":"A. Heidari, J. Esposito, Angela Caissutti","doi":"10.35702/ONC.10007","DOIUrl":"https://doi.org/10.35702/ONC.10007","url":null,"abstract":"1 Citation: Heidari A (2019). The Importance of Attenuated Total Reflectance Fourier Transform Infrared (ATR–FTIR) and Raman Biospectroscopy of Single–Walled Carbon Nanotubes (SWCNT) and Multi–Walled Carbon Nanotubes (MWCNT) in Interpreting Infrared and Raman Spectra of Human Cancer Cells, Tissues and Tumors. Oncogen Journal 2(2): 7. The Importance of Attenuated Total Reflectance Fourier Transform Infrared (ATR–FTIR) and Raman Biospectroscopy of Single–Walled Carbon Nanotubes (SWCNT) and Multi– Walled Carbon Nanotubes (MWCNT) in Interpreting Infrared and Raman Spectra of Human Cancer Cells, Tissues and Tumors Alireza Heidari*1,2, Jennifer Esposito1, Angela Caissutti1","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47482096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-01-30DOI: 10.35702/ONC.10006
C. Maack
{"title":"Triple Hormonal Blockade (ADT3): A Patient’s Perspective","authors":"C. Maack","doi":"10.35702/ONC.10006","DOIUrl":"https://doi.org/10.35702/ONC.10006","url":null,"abstract":"Triple-hormonal blockade/androgen deprivation therapy (ADT3) includes the prescribing of a GnRH agonist or antagonist (I use LHRH and GnRH in the following but in reality, either is appropriate for agonists) to shut down testicular testosterone production; an antiandrogen to block testosterone access to the cancer cell nucleus; and a 5Alpha Reductase (5AR) inhibitor to prevent any testosterone that might access the cancer cell nucleus from converting to dihydrotestosterone/DHT. DHT is a 5 times more powerful stimulant than testosterone to prostate cancer cell growth and proliferation.","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42930256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-01-19DOI: 10.35702/ONC.10005
S. Karakurt, E. Pehlivan, S. Karakurt
{"title":"Removal of Carcinogenic Arsenic from Drinking Water By the Application of Ion Exchange Resins","authors":"S. Karakurt, E. Pehlivan, S. Karakurt","doi":"10.35702/ONC.10005","DOIUrl":"https://doi.org/10.35702/ONC.10005","url":null,"abstract":"Water is the most important source for the sustainability of life. By the increase in the quality of drinking water, life span of the human has increased. Increase in the quality of drinking water is supplied by the removal of toxic contents that are going into the drinking water by either natural ways or by anthropogenic sources. Within the most common toxic materials in water are the trace metals and one of the most important metals in water is arsenic. Organic arsenic species are mostly encountered in the shellfish whereas more toxic inorganic arsenic species get involved in the drinking water by the dissolution of geological formations or as a result of the anthropogenic sources [1, 2]. Trace concentrations of arsenic is vital for hamsters, goats and chickens however, according to the determinations of IARC (International Agency for Research on Cancer), with the increase of the concentration it becomes toxic and carcinogenic [3-6]. Due to these hazardous effects, Removal of Carcinogenic Arsenic from Drinking Water By the Application of Ion Exchange Resins Sevtap Karakurt1, Erol Pehlivan1 and Serdar karakurt2*","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45648179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-01-17DOI: 10.35702/ONC.10003
R. Marri, Harini R Rao, D. Osorio, J. Finlay
{"title":"Hearing Loss, Tinnitus and Pineal Germinoma: Parinaud Dorsal Midbrain Syndrome Revisited","authors":"R. Marri, Harini R Rao, D. Osorio, J. Finlay","doi":"10.35702/ONC.10003","DOIUrl":"https://doi.org/10.35702/ONC.10003","url":null,"abstract":"Henri Parinaud was a French ophthalmologist and neurologist who in 1886 famously described a syndrome in patients with upward gaze paralysis, convergence nystagmus, accommodation paralysis and dilated pupils, some of which he thought were associated with a central lesion. He also described patients with hearing loss in association with this constellation of signs and symptoms, and he was “more disposed to believe that the troubles of hearing and of vision arise from the same central lesion [1]. He concluded by suggesting that “the lesion, instead of directly attacking the bulbo-pontal nuclei, is situated in a neighboring centre, which acts immediately upon them, and it appears that this centre may be the tubercula quadrigemina [1].","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44453412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-01-15DOI: 10.35702/ONC.10004
Seidler Sj, H. De
{"title":"Breast Metachronous Carcinoma and Sarcoma in a Young Patient Leading to the Diagnosis of Li-Fraumeni Syndrome","authors":"Seidler Sj, H. De","doi":"10.35702/ONC.10004","DOIUrl":"https://doi.org/10.35702/ONC.10004","url":null,"abstract":"Genetic and familial cancer syndromes are more prevalent in young patients compared to older counterparts. BRCA1 and BRCA2 mutations account for about 10% of all breast cancer cases in young women. Nevertheless, very early onset breast cancer might be the initial presentation of Li-Fraumeni syndrome (LFS). LFS is also known as sarcoma, breast, leukemia and adrenal gland (SBLA) cancer syndrome and is caused by the germline mutation of the TP53 gene, responsible for a wide spectrum of early-onset malignancies [3]. Its transmission is autosomal dominant with a prevalence of around 1/100000 in the general population and 1% of all breast cancers. Half of affected women will develop a cancer by the age 30 and the penetrance of the germline TP53 mutation reaches 100%. Breast cancer is the most common adult malignancy among patients with LFS [4].","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48634123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-01-15DOI: 10.35702/onc.10002
A. Oluyori, G. Olatunji, A. Shaw, Preeti Rastogi, Meena Sanjeev, D. Dipak
{"title":"Chromatographic Fractionation of An Ethanolic Extract of Peels from Ipomoea batatas Lam for Improved Anticancer Activity","authors":"A. Oluyori, G. Olatunji, A. Shaw, Preeti Rastogi, Meena Sanjeev, D. Dipak","doi":"10.35702/onc.10002","DOIUrl":"https://doi.org/10.35702/onc.10002","url":null,"abstract":"In this current work, the n-hexane fraction from an ethanolic \u0000extract of pulverized peel of Ipomoea batatas Lam was \u0000subjected to chromatographic fractionation. Consequently, \u0000the fractions were investigated for their anticancer potential \u0000using the Sulforhodamine-B assay. Chromatographic \u0000fractionation led to n-hexane sub-fractions with greater \u0000anticancer potential. The study highlights the peel of Ipomoea \u0000batatas Lam as a rich dietary source of natural anticancer \u0000molecules which may be developed into nutraceuticals or \u0000serve as new leads in anticancer therapy. \u0000Keywords: Ipomoea batatas; Chromatography; Fractionation; \u0000Anticancer; Sulforhodamine-B","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46206806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}